Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Thomas Meier Ph.D. | Founder & Chairman | 100k | -- | 1962 |
| Mr. Dario Eklund | Chief Executive Officer | 1M | -- | 1968 |
| Mr. Oliver Strub | Head of Compliance | -- | -- | 1963 |
| Mr. Shabir Hasham M.D. | Chief Medical Officer | -- | -- | -- |
| Ms. Catherine Ann Isted A.C.M.A. | Chief Financial Officer | -- | -- | 1975 |
| Mr. Marc Schrader | Chief Technology Officer | -- | -- | -- |
| Dr. Oliver P. Kronenberg | Chief Legal Officer & Corporate Secretary | -- | -- | -- |
| Mr. Neville Kodkani M.D. | Head of Global Marketing & Partner Management | -- | -- | -- |
| Ms. Sarah Holmes-Klotz | Head of People & Culture | -- | -- | -- |
| Mr. Andreas Missy | Executive Vice President of Corporate Planning & Business Development | -- | -- | -- |
Santhera Pharmaceuticals Holding AG
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 44
Description
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
Corporate Governance
Upcoming Events
April 29, 2025 at 10:59 AM UTC
Santhera Pharmaceuticals Holding AG Earnings Date
Recent Events
September 8, 2022 at 12:00 AM UTC
Dividend Date